Steward Partners Investment Advisory LLC raised its stake in shares of Alkermes plc (NASDAQ:ALKS – Get Rating) by 100.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,000 shares of the company’s stock after acquiring an additional 500 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Alkermes were worth $26,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of ALKS. California Public Employees Retirement System lifted its position in Alkermes by 21.0% in the 4th quarter. California Public Employees Retirement System now owns 304,982 shares of the company’s stock worth $7,094,000 after buying an additional 52,967 shares during the last quarter. Renaissance Technologies LLC lifted its position in Alkermes by 1.4% in the 4th quarter. Renaissance Technologies LLC now owns 4,810,945 shares of the company’s stock worth $111,903,000 after buying an additional 66,463 shares during the last quarter. Sarissa Capital Management LP lifted its position in Alkermes by 6.3% in the 4th quarter. Sarissa Capital Management LP now owns 14,040,000 shares of the company’s stock worth $326,570,000 after buying an additional 827,000 shares during the last quarter. Diversified Trust Co lifted its position in Alkermes by 6.2% in the 1st quarter. Diversified Trust Co now owns 25,495 shares of the company’s stock worth $671,000 after buying an additional 1,496 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in Alkermes by 40.1% in the 4th quarter. Assenagon Asset Management S.A. now owns 14,541 shares of the company’s stock worth $338,000 after buying an additional 4,160 shares during the last quarter. 98.93% of the stock is currently owned by institutional investors.
Alkermes Price Performance
Shares of ALKS stock opened at $25.77 on Friday. The stock has a market cap of $4.23 billion, a price-to-earnings ratio of -45.21 and a beta of 0.60. The business’s fifty day moving average is $28.88 and its 200 day moving average is $27.36. Alkermes plc has a twelve month low of $21.24 and a twelve month high of $33.00. The company has a quick ratio of 2.03, a current ratio of 2.39 and a debt-to-equity ratio of 0.27.
Insider Buying and Selling
In other Alkermes news, SVP Christian Todd Nichols sold 7,474 shares of the business’s stock in a transaction on Tuesday, June 21st. The stock was sold at an average price of $28.26, for a total value of $211,215.24. Following the sale, the senior vice president now directly owns 21,035 shares of the company’s stock, valued at $594,449.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.76% of the stock is owned by insiders.
Analysts Set New Price Targets
A number of research firms recently weighed in on ALKS. Stifel Nicolaus boosted their target price on Alkermes to $28.00 in a research report on Wednesday, July 27th. StockNews.com raised Alkermes from a “buy” rating to a “strong-buy” rating in a research note on Thursday, July 28th. Mizuho decreased their price target on Alkermes from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Thursday, July 28th. HC Wainwright lifted their price target on Alkermes from $30.00 to $32.00 in a research note on Thursday, April 28th. Finally, The Goldman Sachs Group started coverage on Alkermes in a research note on Wednesday, April 20th. They issued a “buy” rating and a $35.00 price target on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Alkermes presently has an average rating of “Moderate Buy” and a consensus target price of $30.56.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.
- Get a free copy of the StockNews.com research report on Alkermes (ALKS)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.